207 related articles for article (PubMed ID: 32302695)
1. Targeted delivery of miRNA based therapeuticals in the clinical management of Glioblastoma Multiforme.
Pottoo FH; Javed MN; Rahman JU; Abu-Izneid T; Khan FA
Semin Cancer Biol; 2021 Feb; 69():391-398. PubMed ID: 32302695
[TBL] [Abstract][Full Text] [Related]
2. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
[TBL] [Abstract][Full Text] [Related]
3. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
4. Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival.
Lopez-Bertoni H; Kozielski KL; Rui Y; Lal B; Vaughan H; Wilson DR; Mihelson N; Eberhart CG; Laterra J; Green JJ
Nano Lett; 2018 Jul; 18(7):4086-4094. PubMed ID: 29927251
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.
Shea A; Harish V; Afzal Z; Chijioke J; Kedir H; Dusmatova S; Roy A; Ramalinga M; Harris B; Blancato J; Verma M; Kumar D
Cancer Med; 2016 Aug; 5(8):1917-46. PubMed ID: 27282910
[TBL] [Abstract][Full Text] [Related]
6. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
Gutkin A; Cohen ZR; Peer D
Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review.
Ahir BK; Ozer H; Engelhard HH; Lakka SS
Crit Rev Oncol Hematol; 2017 Dec; 120():22-33. PubMed ID: 29198335
[TBL] [Abstract][Full Text] [Related]
8. Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme.
Akhter MH; Rizwanullah M; Ahmad J; Amin S; Ahmad MZ; Minhaj MA; Mujtaba MA; Ali J
Drug Res (Stuttg); 2021 Mar; 71(3):122-137. PubMed ID: 33167048
[TBL] [Abstract][Full Text] [Related]
9.
Gallego L; Ceña V
Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
[TBL] [Abstract][Full Text] [Related]
10. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy.
Nikaki A; Piperi C; Papavassiliou AG
Expert Opin Investig Drugs; 2012 Oct; 21(10):1475-88. PubMed ID: 22809292
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
[TBL] [Abstract][Full Text] [Related]
12. Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy.
Shatsberg Z; Zhang X; Ofek P; Malhotra S; Krivitsky A; Scomparin A; Tiram G; Calderón M; Haag R; Satchi-Fainaro R
J Control Release; 2016 Oct; 239():159-68. PubMed ID: 27569663
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
14. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment.
Ganipineni LP; Danhier F; Préat V
J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine associated with photodynamic therapy for glioblastoma treatment.
de Paula LB; Primo FL; Tedesco AC
Biophys Rev; 2017 Oct; 9(5):761-773. PubMed ID: 28823025
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
17. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.
Cunha PP; Costa PM; Morais CM; Lopes IR; Cardoso AM; Cardoso AL; Mano M; Jurado AS; Pedroso de Lima MC
Hum Mol Genet; 2017 Nov; 26(22):4375-4387. PubMed ID: 28973155
[TBL] [Abstract][Full Text] [Related]
18. In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
Xiong DD; Xu WQ; He RQ; Dang YW; Chen G; Luo DZ
Oncol Rep; 2019 Apr; 41(4):2194-2208. PubMed ID: 30816530
[TBL] [Abstract][Full Text] [Related]
19. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
[TBL] [Abstract][Full Text] [Related]
20. Relationship between magnetic resonance imaging features and miRNA gene expression in patients with glioblastoma multiforme.
Li WB; Chen HY; Zhang W; Yan W; Shi R; Li SW; Jiang T
Chin Med J (Engl); 2013; 126(15):2881-5. PubMed ID: 23924460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
